Etsuro Matsubara

Dr. Etsuro Matsubara


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2011 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
ATAyumi Takamura
Ayumi Takamura
YOYasuhide Okamoto
Yasuhide Okamoto
TKTakeshi Kawarabayashi
Takeshi Kawarabayashi
TYTatsuki Yokoseki
Tatsuki Yokoseki
MSMasao Shibata
Masao Shibata
EMEtsuro Matsubara
Etsuro Matsubara
Background: Several lines of evidence indicate that memory loss represents a synaptic failure caused by soluble amyloid β (Aβ) oligomers. However, the pathological relevance of Aβ oligomers (AβOs) as the trigger of synaptic or neuronal degeneration, and the possible mechanism underlying the neurotoxic action of endogenous AβOs remain to be determined. Results: To specifically target toxic AβOs in vivo, monoclonal antibodies (1A9 and 2C3) specific to them were generated using a novel design method. 1A9 and 2C3 specifically recognize soluble AβOs larger than 35-mers and pentamers on Blue native polyacrylamide gel electrophoresis, respectively. Biophysical and structural analysis by atomic force microscopy (AFM) revealed that neurotoxic 1A9 and 2C3 oligomeric conformers displayed non-fibrilar, relatively spherical structure. Of note, such AβOs were taken up by neuroblastoma (SH-SY5Y) cell, resulted in neuronal death. In humans, immunohistochemical analysis employing 1A9 or 2C3 revealed that 1A9 and 2C3 stain intraneuronal granules accumulated in the perikaryon of pyramidal neurons and some diffuse plaques. Fluoro Jade-B binding assay also revealed 1A9- or 2C3-stained neurons, indicating their impending degeneration. In a long-term low-dose prophylactic trial using active 1A9 or 2C3 antibody, we found that passive immunization protected a mouse model of Alzheimer's disease (AD) from memory deficits, synaptic degeneration, promotion of intraneuronal AβOs, and neuronal degeneration. Because the primary antitoxic action of 1A9 and 2C3 occurs outside neurons, our results suggest that extracellular AβOs initiate the AD toxic process and intraneuronal AβOs may worsen neuronal degeneration and memory loss. Conclusion: Now, we have evidence that HMW-AβOs are among the earliest manifestation of the AD toxic process in mice and humans. We are certain that our studies move us closer to our goal of finding a therapeutic target and/or confirming the relevance of our therapeutic strategy.

1 January 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
EMEtsuro Matsubara
Etsuro Matsubara
ATAyumi Takamura
Ayumi Takamura
YOYasuhide Okamoto
Yasuhide Okamoto
HOHideto Oono
Hideto Oono
TNTakashi Nakata
Takashi Nakata
MSMikio Shoji
Mikio Shoji
Several lines of evidence indicate that amyloidβ(Aβ), particularly Aβoligomers (AβOs), plays a causative role in Alzheimer's disease. However, the mechanisms underlying the action of an anti-AβO antibody to clarify the toxic action of AβOs remain elusive. Here, we showed that the anti-AβO antibody (monoclonal 72D9) can modify the Aβaggregation pathway. We also found that 72D9 directly sequesters both extracellular and intraneuronal AβOs in a nontoxic state. Thus, therapeutic intervention targeting AβOs is a promising strategy for neuronal protection in Alzheimer's disease.

1 February 2000 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
MSMikio Shoji
Mikio Shoji
TKTakeshi Kawarabayashi
Takeshi Kawarabayashi
EMEtsuro Matsubara
Etsuro Matsubara
MIMasaki Ikeda
Masaki Ikeda
KIKoji Ishiguro
Koji Ishiguro
KOKoichi Okamoto
Koichi Okamoto

1 April 1999 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
EMEtsuro Matsubara
Etsuro Matsubara
JGJorge Ghiso
Jorge Ghiso
BFBlas Frangione
Blas Frangione
MAMasakuni Amari
Masakuni Amari
YTYasushi Tomidokoro
Yasushi Tomidokoro
MSMikio Shoji
Mikio Shoji

1 January 2002
Verified
Journal Article
Closed access
EMEtsuro Matsubara
Etsuro Matsubara
MSMikio Shoji
Mikio Shoji
KAKoji Abe
Koji Abe

1 September 2000 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
MSMikio Shoji
Mikio Shoji
MKMitsuyasu Kanai
Mitsuyasu Kanai
EMEtsuro Matsubara
Etsuro Matsubara
MIMasaki Ikeda
Masaki Ikeda
YHYasuo Harigaya
Yasuo Harigaya
SHShunsaku Hirai
Shunsaku Hirai